Last reviewed · How we verify
NCT03525626
Online Mindfulness-based Tic Reduction
NA trial testing Online Mindfulness-based Tic Reduction in Tourette Syndrome in 6 participants. Completed in 7 August 2018.
7 August 2018
Quick facts
| Lead sponsor | Bowdoin College |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 6 |
| Start date | 4 April 2018 |
| Primary completion | 7 August 2018 |
| Estimated completion | 7 August 2018 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Online Mindfulness-based Tic Reduction
Conditions studied
- Tourette Syndrome — all drugs for Tourette Syndrome →
- Tic Disorders — all drugs for Tic Disorders →
Sponsor
Bowdoin College
Who can join
18 and older, any sex, with Tourette Syndrome or Tic Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tourette Syndrome (TS) and Persistent Tic Disorder (PTD) are chronic and potentially disabling neurobiological conditions. Although a range of pharmacological and psychosocial treatments exists, a significant number of individuals either do not respond to the current treatments, find them unacceptable, or cannot access them. Thus, it is essential that researchers continue to pursue novel treatment approaches that can also be easily disseminated to those in need. Initial pilot data suggest that a mindfulness-based intervention may be beneficial for adults with tic disorders. In the present study, the researchers aim to further develop this mindfulness-based intervention, adapt it to be delivered online and pilot test the intervention with a small group of participants. The data from this pilot test will inform a subsequent randomized controlled trial comparing online mindfulness-based tic reduction to online psychoeducation, relaxation, and supportive therapy. The specific aim is to determine the feasibility and acceptability of Online Mindfulness-based Tic Reduction in 6 adults with TS or PTD. The researchers hypothesize that Online Mindfulness-based Tic Reduction will be feasible and acceptable to adults with tic disorders as measured by participant satisfaction, qualitative participant feedback, home practice compliance, dropout, and adverse events.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility and acceptability of an online mindfulness-based group intervention for adults with tic disorders.
Reese HE, Brown WA, Summers BJ, Shin J, et al · · 2021 · cited 17× · PMID 33757602 · DOI 10.1186/s40814-021-00818-y
Verify or expand the search:
- PubMed search for NCT03525626
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tourette Syndrome
Currently open trials in the same condition.
- NCT07203469 — Where Wild Things Grow: Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth · NA · recruiting
- NCT06679790 — Trajectories of Change in Tourette Syndrome · NA · recruiting
- NCT06678737 — CBIT+TMS R33 Phase · Phase 2 · recruiting
- NCT06909656 — Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome · NA · recruiting
- NCT06785532 — Effect of RNS in Treatment-refractory Tourette's Syndrome · NA · recruiting
Other Bowdoin College trials
Trials by the same sponsor.
- NCT03771235 — Online Mindfulness-based Tic Reduction (Phase Two) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03525626 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bowdoin College
- Last refreshed: 9 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03525626.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing